Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02590874 · ClinicalTrials.gov registry record · Phase 4
The Use of Duloxetine for Cognition Improvement in Individuals With Mild Cognitive Impairment
A Phase 4 study, sponsored by University of North Texas Health Science Center.
- Completed
- Registry status
- Phase 4
- Development phase
- 19
- Enrollment target
NCT02590874: Completed Phase 4 study, sponsored by University of North Texas Health Science Center.
NCT02590874 is a Phase 4 study that has completed, run by University of North Texas Health Science Center. The registered enrollment target is 19 participants, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (96% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02590874, a Phase 4 study, has completed, sponsored by University of North Texas Health Science Center.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 19 participants
- Enrollment target
Study Summary
The purpose of this study is to determine whether Cymbalta (duloxetine) is effective to improve cognition in individuals with Mild Cognitive Impairment.
Primary Outcome
RBANS measures immediate memory, visuospatial construction, attention processes and speed of information processing, expressive and receptive language, and delayed memory.
Interventions
- DRUG Placebo
- DRUG Duloxetine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 19 participants |
| Start Date | 2016-01 |
| Est. Completion | 2018-10 |
| Phase | Phase 4 |
What the finished NCT02590874 record still lists
NCT02590874 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 19 participants, a relatively small participant target, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (96% lower).
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT02590874 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02590874 about?
NCT02590874 is a clinical study titled "The Use of Duloxetine for Cognition Improvement in Individuals With Mild Cognitive Impairment". The purpose of this study is to determine whether Cymbalta (duloxetine) is effective to improve cognition in individuals with Mild Cognitive Impairment.
What is the current status of trial NCT02590874?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 19 participants. The study started on 2016-01. Estimated completion is 2018-10.
What interventions are being tested in trial NCT02590874?
The interventions under investigation include: Placebo (DRUG), Duloxetine (DRUG).
Who is sponsoring clinical trial NCT02590874?
This trial is sponsored by University of North Texas Health Science Center, which has 21 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02590874's enrollment target sits among peer trials
19 1834th of 2000 higher than 159 of 2,000 other Phase 4 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03207464 · 19 participants · Phase 1
Molecular Imaging of NET Using [C-11]MRB-PET in MS
- NCT04318717 · 19 participants · Phase 2
Pembrolizumab and Hypofractionated Radiation Therapy for the Treatment of Mucosal Melanoma
- NCT05103904 · 19 participants · Phase 2
Lenvatinib for the Treatment of Recurrent Hepatocellular Carcinoma After Liver Transplant
- NCT05607407 · 19 participants · Phase 2
Methimazole in Patients With Progressive Glioblastoma
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia